(Trospium chloride + Xanomeline) is a small molecule commercialized by Karuna Therapeutics, with a leading Phase III program in Psychosis. According to Globaldata, it is involved in 22 clinical trials, of which 9 were completed, 9 are ongoing, 3 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of (Trospium chloride + Xanomeline)’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for (Trospium chloride + Xanomeline) is expected to reach an annual total of $2.36 bn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
(Trospium chloride + Xanomeline) Overview
Xanomeline in combination with trospium chloride is under development for the treatment of psychosis, negative and cognitive symptoms associated with dementia, dementia-related psychosis, schizophrenia as an adjunctive treatment for psychosis associated with Alzheimer’s disease. It is administered orally as a capsule. The drug candidate act by targeting muscarinic acetyl choline receptors. It was also under development for the treatment of bipolar disorder and pain.
Karuna Therapeutics Overview
Karuna Therapeutics is a biopharmaceutical company that focuses on developing medicines for neurological and psychiatric conditions. It is investigating its lead product candidate KarXT, an oral modulator of muscarinic receptors for the treatment of schizophrenia, negative and cognitive symptoms of schizophrenia, and Alzheimer’s disease. The company is also evaluating muscarinic-targeted and target-agnostic drug candidates for various indications. Its lead product candidate combines xanomeline, a novel muscarinic agonist that stimulates muscarinic receptors in the central nervous system. Karuna Therapeutics is headquartered in Boston, Massachusetts, the US.
The company reported revenues of (US Dollars) US$10.6 million for the fiscal year ended December 2022 (FY2022), a decrease of 71.2% over FY2021. The operating loss of the company was US$289.7 million in FY2022, compared to an operating loss of US$144.6 million in FY2021. The net loss of the company was US$276.3 million in FY2022, compared to a net loss of US$143.8 million in FY2021. The company reported revenues of US$0.7 million for the first quarter ended March 2023, a decrease of 87.6% over the previous quarter.
For a complete picture of (Trospium chloride + Xanomeline)’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.